3D Bioprinting in Medical Market By Products and solutions (Bioprinters, Consumables and accessories, Software and services), By Technology (Extrusion based bioprinting, Inkjet based bioprinting, Laser assisted bioprinting, Others), By Application (Tissue engineering and regenerative medicine, Drug discovery and development, Others), By End users (Biotechnology and pharmaceutical companies, Academic and research institutes, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
The global 3D bioprinting in medical market was valued at $1.1 billion in 2022, and is projected to reach $4.9 billion by 2032, growing at a CAGR of 15.5% from 2023 to 2032.
3D bioprinting is an advanced technology that involves the deposition of living cells, biomaterials, and other bioactive substances to create three-dimensional structures that mimic the architecture and function of natural tissues and organs. This innovative approach allows for the precise fabrication of complex biological constructs, enabling applications in regenerative medicine, drug testing, and the potential development of functional tissues or organs for transplantation. The process utilizes computer-aided design (CAD) to guide the deposition of bioink, composed of cells and supportive materials, to construct intricate and customized biological structures.
The 3D bioprinting market is driven by a combination of technological advancements, increasing applications in healthcare and research, rising demand for personalized medicine, and supportive regulatory initiatives. The growing incidence of chronic diseases worldwide, such as heart disease, diabetes, and organ failure, is a significant driver. 3D bioprinting provides a promising avenue for developing replacement tissues and organs for patients suffering from these conditions, thereby driving the market forward. The increase in demand for personalized medicine, which tailors medical treatment to individual patients, fuels the adoption of 3D bioprinting. The ability to create tissues and organs specific to a patient's unique anatomy reduces the risk of rejection and enhances the overall success of transplants, addressing a critical need in healthcare and thereby supporting market growth.
However, high costs of bioprinters, lack of structured regulatory frameworks related to approvals for 3D bioprinters, copyright & patent infringement concerns, biocompatibility issues of 3D-bioprinted medical devices, and lack of technical expertise are the major factors hampering the growth of the market. Conversely, untapped markets in the developing countries are expected to provide lucrative opportunities for the market players.
The 3D bioprinting in medical market is segmented into products & solutions, technology, application, end user, and region. By products & solutions, the market is classified into bioprinters, consumables & accessories, and software & services. By technology, the market is classified into extrusion-based bioprinting, inkjet based bioprinting, laser assisted bioprinting, and others. By application, the market is segregated into tissue engineering & regenerative medicine, drug discovery & development, and others. By end user, the market is classified into biotechnology & pharmaceutical companies, academic & research institutes, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global 3D bioprinting in medical market are Organovo Holdings, Inc., Cyfuse Biomedical K.K., BICO, REGEMAT 3D, Desktop Metal, Inc., Medprin, Shining 3D, CollPlant Biotechnologies Ltd, Advanced Solutions, Inc., and 3D Systems Corporation. Key players operating in the market have adopted product launch, partnership, agreement, acquisition, collaboration, expansion, and product upgrade as their key strategies to expand their product portfolio.
Key Benefits For StakeholdersThis report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the 3d bioprinting in medical market analysis from 2022 to 2032 to identify the prevailing 3d bioprinting in medical market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the 3d bioprinting in medical market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global 3d bioprinting in medical market trends, key players, market segments, application areas, and market growth strategies.
Key Market SegmentsBy End usersBiotechnology and pharmaceutical companies
Academic and research institutes
Others
By Products and solutionsBioprinters
Consumables and accessories
Software and services
By TechnologyExtrusion based bioprinting
Inkjet based bioprinting
Laser assisted bioprinting
Others
By ApplicationTissue engineering and regenerative medicine
Drug discovery and development
Others
By RegionNorth America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa,
Saudi Arabia
Rest of LAMEA
Key Market PlayersCyfuse Biomedical K.K.
BICO
Desktop Metal, Inc.
Medprin
CollPlant Biotechnologies Ltd
3D Systems Corporation
Organovo Holdings, Inc.
REGEMAT 3D
Shining 3D
Advanced Solutions, Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.